Search Results - Pilar Garrido
- Showing 1 - 4 results of 4
-
1
-
2
Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC by Caicun Zhou, MD, PhD, Silvia Novello, MD, PhD, Pilar Garrido, MD, PhD, Christophe Dooms, MD, PhD, Jorge Alatorre-Alexander, MD, Niels Reinmuth, MD, Gill Worthy, PhD, Kim Cocks, PhD, Justin Williams, PhD, Hongmei Han, MS, MApSt, Minji K. Uh, PhD, Nalin Payakachat, PhD, Adrienne M. Gilligan, PhD, Koichi Goto, MD, PhD
Published 2025-07-01
Article -
3
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study) by Miguel García-Pardo, Marta García de Herreros, Edouard Auclin, Miquel Ferriol-Galmes, Juan Carlos Laguna, Teresa Gorría, Gerard Caravaca, Joan Sart, Víctor Albarrán-Artahona, Rafael López-Castro, Cristina Teixidó, Giancarlo Castellano, Alex Martínez Bedmar, Ainara Arcocha, Laura Alcolea, Manuel Jiménez, Mario Bernabeu, David Delgado-Cano, Alejandro Navarro, Aleix Prat, Noemí Reguart, Javier Elio, Pilar Garrido, Natasha B. Leighl, Benjamin Besse, Laura Mezquita
Published 2025-06-01
Article -
4
CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC by Jay M. Lee, MD, Jean-Louis Pujol, MD, PhD, Jun Zhang, MD, PhD, Oleg Leonov, MD, PhD, Masahiro Tsuboi, MD, PhD, Edward S. Kim, MD, MBA, Calvin Ng, MD, Nicolas Moreno-Mata, MD, PhD, Amy Cummings, MD, PhD, Ilhan Hacibekiroglu, MD, Abidin Sehitogullari, MD, Nirmal Veeramachaneni, MD, Cathy Spillane, PhD, Jiawei Duan, PhD, Claudia Bossen, PhD, Alexander Savchenko, MD, PhD, Chiara Lobetti-Bodoni, MD, PhD, Tony Mok, MD, Pilar Garrido, MD
Published 2025-08-01
Article